ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 132

Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients

Chary Lopez-Pedrera1, Mª Ángeles Aguirre-Zamorano 2, Laura Pérez-Sanchez 3, Alejandra Patiño-Trives 1, Maria Luque-Tevar 1, Alejandro Ibañez-Costa 1, Ivan Arias de la Rosa 4, Maria del Carmen Abalos-Aguilera 1, Lourdes Alacaide-Ruggiero 5, Rafaela Ortega 1, Nuria Barbarroja 6, Eduardo Collantes-Estevez 4, Massimo Radin 7, Irene Cecchi 7, Savino Sciascia 8 and Carlos Perez-Sanchez 9, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 3MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 4University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, 5University of Cordoba, Cordoba, Spain, 6University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, 7University of Turin, Turin, Italy, 8Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy, 9Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: and autoantibodies, Antiphospholipid antibodies, antiphospholipid syndrome, Genetic Biomarkers

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The clinical significance of non-canonical anti-phosphatidylserine/prothrombin (aPS/PT) antibodies in antiphospholipid syndrome (APS) is still controversial. This study assessed the prevalence of aPS/PT antibodies, their association with different APS clinical phenotypes and their involvement in the serum and monocytes molecular profiles.

Methods: Forty APS patients and 40 healthy donors were examined. Anti-cardiolipin (aCL), anti-β2GP-I and aPS/PT antibodies (IgG, IgM and IgA isotypes), as well as lupus anticoagulant (LA) were tested. In parallel, monocytes from peripheral blood were purified by positive immunomagnetic selection. Gene expression microarray (Agilent GF112F) and nCounter microRNA expression array (Nanostring) were performed. Separately, a miRNA array in the plasma of those patients was performed, along with the analysis of their inflammatory profile by multiplex assay. Selected genes and miRNAs found significantly altered and related to the prothrombotic and obstetric pathology in APS were validated in the whole cohort by qPCR. The involvement of the presence and titers of canonical and non-canonical autoantibodies on the altered inflammatory and gene/miRNA profiles were assessed by multiple comparison tests.

Results: aPS/PT antibodies were detected in 11 out of 26 APS patients (42,3%): 6 carriers of the IgM isotype, 1 carrier of IgA isotype, 1 carrier of both IgM and IgA isotypes and 3 carriers of the three isotypes (IgG/IgA/IgM) simultaneously. The 3 isotypes of aPS/PT antibodies were significantly associated with isolated LA positivity. Among them, there was a prevalence of IgM aPS/PT antibodies in thrombotic patients, and of IgA aPS/PT antibodies in patients with obstetric complications. Levels of IgM aPS/PT were significantly different in APS patients with thrombotic manifestations and those with fetal loss.

 Inflammatory profile in plasma of APS patients positive for these non-canonical antibodies showed significantly increased levels of a number of pro-inflammatory mediators (IL2, IL4, IL6, INFg, IL8, IL10, IL12, IL17, GM-CSF, MIP1a, MIP1b) in relation to patients positive for canonical antibodies, along with reduced levels of serum miR26a-5p.

Accordingly, monocytes from APS patients positive for aPS/PT displayed slightly distinctive gene/miRNA profiles related to atherosclerosis and thrombosis than those negative for non-canonical antibodies compared with HDs. Moreover, increased IFNg mRNA classified patients positive or negative for aPS/PT antibodies. This IFNg altered expression might be related to the occurrence of obstetrical complications, as observed by its increased expression in aPS/PT positive obstetric patients in relation to thrombotic patients.

Conclusion: Conclusions: Anti-PS/PT antibodies are frequent in primary APS patients positive for other antiphospholipid antibodies, are associated with different clinical features, and confer distinctive molecular profiles. Thus, anti-PS/PT antibodies might constitute a useful serological tool in the diagnosis, phenotypic and molecular characterization of APS patients.

 Funded by ISCIII, PI18/00837 and RIER RD16/0012/0015 co-funded with FEDER


Disclosure: C. Lopez-Pedrera, None; M. Aguirre-Zamorano, None; L. Pérez-Sanchez, None; A. Patiño-Trives, None; M. Luque-Tevar, None; A. Ibañez-Costa, None; I. Arias de la Rosa, None; M. Abalos-Aguilera, None; L. Alacaide-Ruggiero, None; R. Ortega, None; N. Barbarroja, None; E. Collantes-Estevez, None; M. Radin, None; I. Cecchi, None; S. Sciascia, None; C. Perez-Sanchez, None.

To cite this abstract in AMA style:

Lopez-Pedrera C, Aguirre-Zamorano M, Pérez-Sanchez L, Patiño-Trives A, Luque-Tevar M, Ibañez-Costa A, Arias de la Rosa I, Abalos-Aguilera M, Alacaide-Ruggiero L, Ortega R, Barbarroja N, Collantes-Estevez E, Radin M, Cecchi I, Sciascia S, Perez-Sanchez C. Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/anti-phosphatidylserine-prothrombin-antibodies-confer-a-distinctive-molecular-profile-in-primary-antiphospholipid-syndrome-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-phosphatidylserine-prothrombin-antibodies-confer-a-distinctive-molecular-profile-in-primary-antiphospholipid-syndrome-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology